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Abstract
Background: Vitronectin is an abundant plasma glycoprotein identified also as a part of extracellular matrix. Vitronectin is
substantially enriched at sites of injured, fibrosing, inflamed, and tumor tissues where it is believed to be involved in wound
healing and tissue remodeling. Little is known about the mechanism of vitronectin localization into the damaged tissues.
Methodology/Principal Findings: 2E12 antibody has been described to bind a subset of late apoptotic cells. Using
immunoisolation followed by mass spectrometry, we identified the antigen recognized by 2E12 antibody as vitronectin.
Based on flow cytometry, we described that vitronectin binds to the late apoptotic and necrotic cells in cell cultures in vitro
as well as in murine thymus and spleen in vivo. Confocal microscopy revealed that vitronectin binds to an intracellular
cytoplasmic structure after the membrane rupture.
Conclusions/Significance: We propose that vitronectin could serve as a marker of membrane disruption in necrosis and
apoptosis for flow cytometry analysis. Moreover, we suggest that vitronectin binding to dead cells may represent one of the
mechanisms of vitronectin incorporation into the injured tissues.
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Introduction
Apoptosis and necrosis represent two fundamental types of cell
death. While necrosis is usually viewed as a more or less passive
cell rupture caused by excessive exogenous damage, apoptosis is
an active process consisting of highly coordinated molecular events
leading to a sequence of morphological changes and is
accompanied by modifications of the cellular surface. The cell
loses its surface anti-phagocytic ‘‘don’t-eat-me’’ signals (mediated
mostly by CD31 and CD47 glycoproteins) and exposes ligands
designating the cell for phagocytosis (e.g. phosphatidylserine) [1,2].
Moreover, several extracellular molecules bind to the apoptotic
cells (e.g. MFG-E8, TSP-1, complement factors) facilitating
phagocytosis [1–3]. Importantly, the early apoptotic cells preserve
their plasma membrane integrity to retain the potentially harmful
cellular contents inside. If not successfully taken up by phagocytes,
apoptotic cells proceed to the phase of late apoptosis (termed also
secondary necrosis) when the plasma membrane becomes
permeable for small molecules (e.g. propidium iodide (PI)) and
subsequently also for macromolecules (proteins) [4]. The leakage
of intracellular molecules during secondary necrosis provokes an
inflammatory response, explaining why defective apoptotic cell
clearance is associated with autoimmune diseases [3].
Reagents specifically recognizing the cells at particular stages of
apoptosis can be useful research and diagnostic tools. A
monoclonal antibody 2E12 has been reported to recognize a
subset of apoptotic cells in culture [5,6]. However, the precise
identity of this subset as well as the molecule recognized by this
antibody have remained unknown. Here we show that the 2E12
antibody recognizes bovine serum protein vitronectin (originating
from cell culture medium) bound to the late apoptotic cells.
Vitronectin is a major plasma glycoprotein produced mainly in
the liver where it is released into the circulation [7,8]. It is also a
part of extracellular matrix, substantially enriched at sites of
injured, fibrosing, inflamed, and cancer tissue [8–12].
Vitronectin was initially described as an inhibitor of comple-
ment terminal pathway and a regulator of blood homeostasis [13–
15]. In addition, it contributes to tissue remodeling and healing by
regulation of proteolysis, cell adhesion, migration, and survival in
the injured tissue [10,15–22]. Moreover, vitronectin probably
enhances migration of leukocytes into the stressed tissue
[10,19,23]. On the other hand, vitronectin also stimulates tumor
invasiveness and contributes to the development of chronic tissue
injuries [15,24,25]. Known binding partners mediating cell
interactions with vitronectin-containing tissues include integrins
(aVb3, aVb5, aVb1, aVb6, aVb8, and aIIbb3) and the urokinase
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deposition of vitronectin in the stressed tissues remains still
incompletely understood [8,15].
Here we bring evidence that vitronectin binds to an intracellular
component of cells in the latest stage of apoptosis and of necrotic
cells in vitro as well as in vivo, which could represent an important
mechanism facilitating vitronectin incorporation into the sites of
tissue injury.
Materials and Methods
1. Antibodies and proteins
Antibodies to the following antigens were used: human
vitronectin (VN58-1, mouse, Abcam, Cambridge, MA, USA),
human albumin (AL-01, mouse, Exbio, Vestec, Czech Republic),
human cytokeratin-Alexa Fluor 488 (pan-reactive, Exbio), human
vimentin-Dy-547 (Exbio), bovine vitronectin (rabbit, Acris Anti-
bodies, Herford, Germany), mouse vitronectin (347317, rat, R&D
Systems, Minneapolis, MN, USA), mouse Ig-HRP (goat, Bio-Rad,
Hercules, CA, USA), rabbit Ig-HRP (goat, Bio-Rad), mouse Ig-
Alexa Fluor 488 (goat, Invitrogene, Carlsbad, CA, USA), mouse
Ig-Alexa Fluor 647 (goat, Invitrogen), and rat Ig-Allophycocyanin
(APC) (goat, BD Bioscience, Franklin Lakes, NJ, USA). The
following isotype matched controls were used: Rat IgG2a
(eBioscience, San Diego, CA, USA) and anti-HLA-DR (mouse
IgG1, MEM-12, in house). Following proteins and peptides were
used: human vitronectin (Technoclone, Dorking, UK), biotiny-
lated human vitronectin (Cell Sciences, Sharon, MA, USA),
bovine vitronectin (Sigma-Aldrich, St. Louis, MO, USA), RGD
peptide (Sigma-Aldrich), streptavidin-Alexa Fluor 488 (Invitro-
gene), Annexin-V-FITC, Annexin-V-Dy647 (both Apronex,
Prague, Czech Republic). Mouse monoclonal antibody 2E12
(IgG1) was described previously [5].
2. Cell culture
Human cell lines Jurkat (American Type Culture Collection,
Manassas, VA, USA), HeLa (provided by D. Stanek, IMG, Prague,
Czech Republic), JCaM2.5 (A. Weiss, University of California, San
Francisco,CA,USA),Ramos,HL-60(bothAmerican Type Culture
Collection), chicken cell line DT40 (J. Wienands, University of
Go ¨ttingen, Germany), rabbit cell line 240E1 (K. Knight, Loyola
University Chicago, Maywood, IL, USA), mouse cell lines SP2/0
(American Type Culture Collection), P815 (H. Stockinger, Medical
University of Vienna, Austria) were cultivated in RPMI 1640
medium containing 10% fetal bovine serum (FBS), 2 mM
glutamine, 20 mg/ml gentamycin, 50 mg/ml streptomycin, and
10
4 U/ml penicillin at 37uCi n5 %C O 2.
A green fluorescent protein (GFP) expressing Jurkat cell line
(provided by M. Hrdinka, IMG, Prague) was prepared by
electroporation (250 V, 950 mF) of pZRD (15 mg) vector [26] in
RMPI (300 ml) using a GenePulser electroporator (Bio-Rad
Laboratories, Hercules, CA, USA) followed by zeocin selection
(200 mg/ml, Invitrogen).
Apoptosis was induced by TRAIL ligand (300 ng/ml, Apronex)
or camptothecin (1 mM, Sigma-Aldrich) for the indicated time
period. Inhibition of apoptosis was performed with pan-caspase
inhibitor Z-VAD-FMK (10 mM, Enzo Life Sciences, Inc., Farm-
ingdale, NY, USA). Necrosis was induced by incubation at 65uC
for 40 minutes or by hydrogen peroxide (2 mM) in combination
with Z-VAD-FMK (10 mM).
3. Flow cytometry and confocal microscopy
Viable, apoptotic, or necrotic Jurkat cells were stained with a
primary antibody followed by a corresponding secondary antibody
(both in PBS/1% BSA, on ice, 30 min). Alternatively, cells were
incubated with biotinylated vitronectin (3.6 mg/ml) followed by
streptavidin-Alexa Fluor 488 (both in PBS/1% BSA, on ice,
30 min). Stages of cell death were examined by staining with
Annexin-V, PI (1 mM, Sigma-Aldrich), and/or Hoechst 34580
(2 mg/ml, Invitrogen) (Annexin binding buffer or PBS/1% BSA,
on ice, 30 min). For DNA content analysis, the cells were
incubated with Hoechst 34580 (5 mg/ml, 37uC, 20 min). For
microscopy, cells were transferred into Lab-Tek chambers
(Thermo Fisher Scientific, Waltham, USA) in Annexin binding
buffer.
HeLa cells were fixed (PBS/4% formaldehyde), permeabilized,
and blocked (PBS/5% BSA/0.3% Triton-X 100). The cells were
incubated with human serum at 37uC followed by staining with
primary and secondary antibodies at room temperature. Serum
and antibodies were diluted in PBS/1% BSA/0.3% Triton-X 100.
For microscopy, the cells were stained with Hoechst 34580 (2 mg/
ml) for 5 minutes.
Spleens and thymi were collected from healthy 8–9 weeks old
C57Bl/6j mice (IMG Animal Facility). Single-cell thymocyte or
splenocyte suspensions were prepared followed by erythrocyte lysis
in ACK buffer. Approximately 2610
6 cells were stained with anti-
vitronectin or isotype matched control antibodies followed by
incubation with APC-conjugated secondary antibody (PBS/20%
goat serum, on ice, 30 min). Finally, the cells were stained with
Annexin-V-FITC, PI, and Hoechst 34580 (Annexin binding
buffer, on ice, 30 min). Mice used as the source of splenocytes
and thymocytes were kept under the conditions required by
national guidelines for the use of experimental mice and their use
was approved by the Animal Welfare Commission of the Institute
of Molecular Genetics, Academy of Sciences of the Czech
Republic, permit No. 46817/2007 valid for 2007–2011.
Flow cytometry samples were analyzed on LSRII or FACSca-
libur apparatus (BD Biosciences). Data were analyzed using
FlowJo software (TreeStar, San Carlos, CA, USA). Images were
acquired with a Leica SP5 confocal microscope using a 1006
objective lens (Leica Microsystems, Mannheim, Germany). Data
were analyzed using LAS AF 2.00 software (Leica).
4. Quantification of GFP release to the medium
4610
6 wild type or GFP-expressing Jurkat cells were transferred
to fresh RPMI/10% FBS at high cell density (2.5610
6 cells/ml)
and apoptosis was induced by camptothecin. At indicated time
points, 150 ml of the suspension was taken, centrifuged, and the
cell free supernatant was kept in 37uC. After the collection of all
samples, fluorescence intensity (excitation 475 nm, emission
510 nm) of each sample (100 ml) was measured by InfiniteM200
microplate reader (Tecan Group Ldt., Mannedorf, Switzerland).
The GFP fluorescence in medium was obtained by subtraction of
the background fluorescence of the respective samples from GFP-
negative Jurkat cultures.
5. Immunoisolation
2E12 or isotype matched control antibodies were covalently
bound to CNBr-activated Sepharose (Sigma-Aldrich) according to
the manufacturer’s instructions. Immunoaffinity chromatography
was performed at 4uC on minicolumns containing 40 ml of the
immunosorbent. FBS (100 ml) was applied at the top of the
minicolumn followed by PBS wash (400 ml). The adsorbed
proteins were eluted with 80 ml of 0.1 M triethanolamine
(pH 11.5). Subsequently, pH of the eluted fraction was adjusted
with 10 ml 1 M Tris/HCl (pH 8.2). Finally, the material was
mixed 1:1 with 26 concentrated Laemmli sample buffer (non-
reducing or reducing with final 0.5% dithiothreitol) and subjected
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Rad) staining or immunoblotting.
6. Mass spectrometry analysis
Preparation of the sample and analysis by an ion trap mass
spectrometer (LCQ
DECA, ThermoElectron, Waltham, MA, USA)
was performed as described previously [27]. The instrument was
set to acquire a full MS scan between 350–1800 m/z followed by
MS/MS scan of the most intense ion from the preceding scan. The
MS/MS data were searched against NCBI non-redundant
database with SEQUEST software (Thermo Fisher Scientific) as
described previously [28].
7. Binding of vitronectin to red blood cells
RBCs were isolated from a blood of a healthy donor using
Histopaque-1119 (Sigma-Aldrich) gradient. RBCs (10% v/v in
PBS/0.5 mM MgCl2/1 mM CaCl2) were biotinylated with sulfo-
NHS-LC-biotin (300 mM, Pierce, Rockford, IL, USA) on ice for
1 hour. RBCs were washed twice and incubated in the presence of
streptavidin (40 mg/ml, Jackson ImmunoResearch, West Grove,
PA, USA) on ice for 30 minutes. RBCs were washed twice and
incubated with biotinylated human vitronectin (72 mg/ml) on ice
for 30 minutes. The blood sample was obtained from one of the
authors of this study (O.S.) based on his written consent. The
Commission for Ethics and Work with Recombinant DNA and
Human Materials of the Institute of Molecular Genetics, Academy
of Sciences of the Czech Republic, exempted this study from
review because it considered the written informed consent
ethically unproblematic.
Results
1. 2E12 antibody specifically binds late apoptotic cells
cultured in the presence of bovine serum
Monoclonal antibody 2E12 recognized a subpopulation of
Jurkat T cells in culture, as revealed by flow cytometry (Fig. 1A).
The frequency of 2E12-positive cells varied, depending on the
viability of the particular culture. Overgrown cultures (approx.
2610
6 cells/ml) contained more cells stained with 2E12 than
cultures in optimal growth conditions (,10
6 cells/ml) (Fig. 1A–B).
The 2E12-positive cells exhibited features of cell death as indicated
by forward and side scatter analysis and Annexin-V staining
(Fig. 1A–B). In contrast to previously published data [5], these cells
were stained with PI, indicating that the plasma membrane was
not intact (Fig. 1B). However, cells, that were most intensively
stained with PI, were 2E12-negative. The intermediate PI signal of
the 2E12-positive cells can be explained by low DNA content as
shown by Hoechst 34580 staining (Fig. 1B).
We induced apoptosis in Jurkat cells and monitored them using
Annexin-V, PI, and 2E12 staining over time. We distinguished
three populations of apoptotic cells: Annexin-V
+/PI
2, Annexin-
V
+/PI
+/2E12
2, and Annexin-V
+/PI
+/2E12
+ (Fig. 1C). The
Annexin-V
+/PI
2 population that peaked early after apoptosis
induction and diminished over time, was identified as early
apoptotic cells. Secondary necrotic cells defined as Annexin-V
+/
PI
+ appeared later. Interestingly, the increase of Annexin-V
+/PI
+/
2E12
+ cells was observed after 48 hours, suggesting that the 2E12-
positive cells represent the latest stage of apoptosis progression.
We performed a comparison between the 2E12-positivity and
intracellular protein release after apoptosis induction over time.
Jurkat cell line producing cytosolic GFP was subjected to apoptosis
induction with camptothecin at high cell density. The kinetics of
the GFP release to the medium was strikingly similar to the
increase of the percentage of the 2E12-positive cells over time
(Fig. 1D). This observation suggests that the cells stained with
2E12 are the source of GFP released to the medium. The 2E12
antibody obviously recognizes cells with severely damaged plasma
membrane, permeable for large molecules like proteins.
We tested six cell lines of different origin (human, chicken,
rabbit, and mouse) cultured in the presence of fetal bovine serum
(FBS) for 2E12 positivity. In all cases a hypodiploid 2E12-positive
population was detected (Fig. S1). This led us to hypothesize that
the 2E12 antibody might recognize a bovine serum component
specifically bound to late apoptotic cells. Thus, we prepared late
apoptotic Jurkat cells in serum-free medium followed by a short
incubation in FBS prior to 2E12 staining. The serum-treated cells,
but not cells held in serum-free conditions, became 2E12-positive
(Fig. 1E), which pointed to the serum origin of the molecule
recognized by the 2E12 antibody. Extension of this assay to sera
from different species revealed that short incubation in bovine or
goat but not in rat, guinea pig, or human sera resulted in
recognition of the late apoptotic cells by the 2E12 antibody
(Fig. 1F).
2. 2E12 antibody recognizes bovine vitronectin
To identify the bovine serum component recognized by the
2E12 antibody, we subjected the serum to immunoisolation on
immobilized 2E12 antibody. Separation of the immunoprecipitat-
ed material by SDS-PAGE under non-reducing conditions
followed by Coomassie Blue protein staining detected a single
major protein (ca 70–80 kDa) that was immunoisolated using the
2E12 antibody but not an isotype matched control antibody
(Fig. 2A). The stained zone was cut from the gel, trypsin digested,
and analyzed by tandem mass spectrometry. Bovine vitronectin
(accession number 78045497) was the only protein identified in the
sample. The final protein coverage was 39% with 15 peptides
spread over the whole protein sequence (AA 38 to 476). To
confirm that 2E12 antibody is specific for bovine vitronectin, we
immunoblotted purified vitronectin standard side by side with the
material immunoisolated by means of the 2E12 antibody. Both
2E12 antibody and a commercial polyclonal antibody to bovine
vitronectin stained the immunoisolated material as well as the
vitronectin standard (Fig. 2B). Furthermore, when unseparated
FBS was subjected to Western blotting, 2E12 antibody detected
only a doublet corresponding by m.w. to vitronectin and not any
other of the multiple bovine serum components (not shown). Thus,
it can be safely concluded that the 2E12 antibody recognizes
bovine vitronectin and that the material immunoisolated from
FBS by means of the 2E12 antibody contains vitronectin (Fig. 2B).
The presence of the two bands observed in the Western blots is
caused by reduction of the sample with dithiothreitol that reveals
the previously described single-chain (75 kDa) and two-chain
(65+10 kDa) vitronectin forms [7].
3. Vitronectin binds late apoptotic cells directly
After we identified that bovine serum vitronectin binds to late
apoptotic cells, we decided to study the interaction in more detail.
We switched to a purely human model system to avoid any
potential complications resulting from interspecies incompatibili-
ties at the molecular level and repeated the vitronectin binding
assay using Jurkat cells, human serum, and antibody to human
vitronectin. The late apoptotic cells were again recognized by anti-
vitronectin antibody only after incubation in human serum
(Fig. 3A). The percentage of human vitronectin-positive cells
increased after apoptosis induction when cultivated in human
serum-containing medium (Fig. S2) and followed similar kinetics to
2E12-positive cells in RMPI/10% FBS (Fig. 1C). To test whether
binding to late apoptotic cells is a specific feature of vitronectin, we
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19243Figure 1. 2E12 antibody recognizes a serum component bound to late apoptotic cells. (A) Jurkat cells were stained with 2E12+GAM-Alexa
Fluor 488 (black line) antibodies or GAM-Alexa Fluor 488 only (grey filled histogram) and analyzed by flow cytometry (left panel). Forward scatter
(FSC) vs. side scatter (SSC) plot shows 2E12 negative (gray) and 2E12 positive (black) Jurkat cells (right panel). The cell culture was grown to density
about 2610
6 cells/ml. (B) Jurkat cells were stained with Annexin-V, PI, Hoechst 34580, and 2E12 + GAM-Alexa Fluor 647 antibodies and analyzed by
flow cytometry. (C) Apoptosis was induced in Jurkat cells by camptothecin. The cells were examined for Annexin-V-FITC, PI, and 2E12 + GAM-Alexa
Fluor 647 staining by flow cytometry at indicated time points. Mean 6 SD, n=3. (D) Wild type or intracellular GFP expressing Jurkat cells were
transferred to fresh medium prior to apoptosis induction with camptothecin at high cell density (2.5610
6/ml). At indicated time points, 150 ml of the
culture was taken up. The cells were stained with 2E12 antibody followed by flow cytometry analysis while the cell-free supernatant was collected.
The release of GFP to medium in all samples was measured by fluorescence plate reader at the end of the experiment. The values represent net GFP
fluorescence after the subtraction of the background fluorescence intensity of the medium from wild type Jurkat cells. Mean 6 SD, n=3. (E)
Apoptosis was induced in Jurkat cells by TRAIL in serum-free medium (containing 1% BSA). After 72 hours, one half of the cells were incubated in
50% FBS for 1 hour. Finally, both 50% FBS-treated and untreated cells were stained with 2E12 + GAM-Alexa Fluor 488 antibodies and analyzed by flow
Vitronectin in Late Apoptotic and Necrotic Cells
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vitronectin and human albumin. Although albumin is 300 times
more abundant than vitronectin in plasma [29] and the anti-
albumin antibody produced a much stronger signal than the anti-
vitronectin antibody in ELISA assay on human serum (not shown),
the signal produced by anti-albumin antibody on the serum-
incubated late apoptotic cells was negligible compared to the anti-
vitronectin antibody (Fig. 3B). This indicated the specificity of the
vitronectin binding. Given the multiplicity of known vitronectin-
binding partners in plasma [7], it was unclear whether vitronectin
binds the late apoptotic cells directly or uses another serum
component as a molecular bridge. We incubated the late apoptotic
cells in serum-free medium with various concentrations of purified
vitronectin. Vitronectin bound to the cells in a dose dependent
manner indicating a direct interaction between vitronectin and the
late apoptotic cells (Fig. 3C).
Live cells are able to interact with vitronectin via several
integrin receptors. However, high concentrations of EDTA or the
integrin-blocking peptide (RGD) did not prevent binding of serum
vitronectin to late apoptotic cells, excluding the possibility that the
interaction was mediated by integrins (Fig. 3D). Surprisingly, both
EDTA and the RGD peptide even enhanced the signal intensity
after anti-vitronectin antibody staining. On the other hand,
heparin, a well established vitronectin interaction partner [29],
was able to block binding of serum vitronectin to late apoptotic
cells in a dose dependent manner (Fig. 3D). A possible explanation
of this observation could be that heparin binding prevents
recognition of the vitronectin molecule by the antibody. Thus,
we prepared biotinylated red blood cells with bound biotinylated
vitronectin using streptavidin as a bridge and examined the ability
of anti-vitronectin antibody to recognize vitronectin in the
presence of heparin. In this assay, heparin had no effect on the
signal intensity (Fig. 3E), supporting the conclusion that heparin
blocks vitronectin binding to the late apoptotic cells.
4. Vitronectin binds inside the damaged cells
Late apoptotic cells share many features with necrotic cells (e.g.
damaged plasma membrane). We tested the ability of serum
vitronectin to bind Jurkat cells after heat-induced necrosis.
Necrotic, but not viable, cells became positive for vitronectin after
incubation in human serum (Fig. 4A).
We employed confocal microscopy to see whether vitronectin
binds to the surface or inside the late apoptotic cells. Anti-
vitronectin staining combined with Annexin-V membrane staining
revealed clear surface localization of Annexin-V contrasting with
diffuse intracellular staining for vitronectin in the late apoptotic
cells and apoptotic bodies (Fig. 4B). As the cells were not fixed or
permeabilized prior to the staining, the intracellular vitronectin
signal implied that the late apoptotic cell membranes were
permeable for vitronectin as well as for the antibodies. Regions
of apoptotic fragmented nuclei stained by Hoechst 34508 were
devoid of vitronectin indicating that vitronectin bound to
cytoplasmic structures inside the late apoptotic cells (Fig. 4B).
The vitronectin staining produced no signal when the pre-
incubation in human serum was omitted; thus confirming the
signal specificity (not shown). Additionally, microscopy also
supported our flow cytometric data (Fig. 1B) demonstrating that
vitronectin-positive cells contain only small amounts of DNA
(Fig. S3).
5. Intermediate filaments do not mediate vitronectin
binding
Since we detected vitronectin inside the ruptured apoptotic and
necrotic cells, we hypothesized that the vitronectin binding partner
might be present inside intact viable cells, but it is inaccessible to
vitronectin due to the barrier represented by the plasma
membrane. We tested the hypothesis using viable HeLa cells after
detergent permeabilization. As expected, fixed and permeabilized
HeLa cells interacted with human serum vitronectin in a heparin
sensitive manner (Fig. 5A).
As vitronectin was shown to interact with vimentin and
cytokeratins in vitro [30,31], intermediate filament proteins
seemed to be good candidates for vitronectin binding. However,
confocal microscopy showed a diffuse cytoplasmic pattern of
vitronectin staining in permeabilized HeLa cells after incubation
in human serum. Moreover, vitronectin did not co-localize with
vimentin or cytokeratins (Fig. 5B) indicating that vitronectin
interacts with a cytoplasmic structure different from intermediate
filament proteins.
6. Vitronectin binds late apoptotic/necrotic cells in vivo
Experiments performed on cell cultures showed that serum
vitronectin bound to the late apoptotic and necrotic cells in vitro.
To elucidate whether vitronectin binds to the dead cells in vivo,
we analyzed murine splenocytes and thymocytes in a four-colour
flow cytometry assay. The cells were stained simultaneously with
Hoechst 34580, PI, and Annexin-V for identification of late
apoptotic/necrotic cells and with a rat antibody to mouse
vitronectin. The splenocyte cell suspension contained about 1–
2% of Hoechst 34580/PI/Annexin-V-triple positive necrotic/
late apoptotic cells. Majority of these cells were positive for
vitronectin, in contrast to essentially vitronectin-negative viable
splenocytes (Fig. 6A). Thymus contained about 0.5% of late
apoptotic/necrotic cells. About one quarter of these cells in
thymus were positive for vitronectin whereas viable thymocytes
were not stained with the anti-vitronectin antibody at all
(Fig. 6B). The staining procedure was performed in the presence
Figure 2. 2E12 antibody recognizes bovine serum vitronectin.
(A) Immunosorbents made of 2E12 or isotype-matched control
antibodies were used for immunoisolation from bovine serum of the
antigen recognized by the 2E12 antibody. The immunoisolated material
was separated by non-reducing SDS-PAGE followed by Coomassie
staining. The band isolated specifically by 2E12 is marked by black
arrow. (B) Purified vitronectin standard or the 2E12 immunoprecipitate
were immunoblotted (reducing conditions) and stained with 2E12 (left
membrane) or commercial rabbit antibody to bovine vitronectin (right
membrane). Vn, vitronectin.
doi:10.1371/journal.pone.0019243.g002
cytometry. (F) Cells were prepared as in (E) except that the apoptotic cells were incubated with 50% bovine, rat, guinea pig, goat, or human sera or
left untreated prior to 2E12 staining and analysis. Mean 6 SD, n=3. RMFI, relative mean fluorescence intensity.
doi:10.1371/journal.pone.0019243.g001
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mouse vitronectin (not shown). These results support the
conclusion that vitronectin binds the late apoptotic/necrotic
cells also in vivo.
7. Vitronectin as a tool for monitoring of cell death
As demonstrated above, vitronectin binds to cells with ruptured
membrane in vitro and in vivo. When cells die in the presence of
serum, the antibody recognizing vitronectin of the respective
species can be used for detection of the terminal cell death phase
(Fig. 1C, Fig. S2). If the cells are cultivated in the absence of
vitronectin, a short incubation in the presence of serum or purified
vitronectin must be included prior to the staining procedure (e.g.
Fig 3A–C). Based on these results we developed an easy two-step
cytofluorometric method for evaluation of the cell membrane
integrity that works in all conditions regardless of the cultivation
medium.
We induced apoptosis of Jurkat cells with TRAIL in FBS-
containing medium for 24 hours. The cells were stained with
biotinylated vitronectin which was detected with streptavidin
conjugated with Alexa Fluor 488 dye followed by flow cytometry.
The number of vitronectin-positive cells increased after the
apoptosis induction, showing that the method is compatible with
cultivation in the presence of serum (Fig. 7A). Subsequently, we
used this method for monitoring of cell cultures after apoptosis
induction over time (Fig. 7B). The percentage of vitronectin-
stained cells increased as the apoptosis progressed. No early
apoptotic cells (AnnexinV
+/PI
2) nor vitronectin-stained cells
appeared when the TRAIL-induced apoptosis was blocked with
pan-caspase inhibitor Z-VAD, confirming that the vitronectin-
positive cells were apoptotic.
As shown above, heat-induced necrotic cells become vitro-
nectin-positive (Fig. 4A). However, necrosis can be induced by a
milder stimulus that does not destroy cells immediately. Thus,
we induced necrosis with hydrogen peroxide in combination
with Z-VAD (to prevent possible apoptosis) and compared the
cell death progression with TRAIL-induced apoptosis under
serum-free conditions. Interestingly, the percentage of vitronec-
tin-stained cells increased much more rapidly in the necrotic
culture than in the apoptotic one (Fig. 7C). A triple staining with
Annexin-V-Dy647, propidium iodide, and vitronectin showed
that the character of the Annexin-V-positive cells differs
substantially between the apoptotic and necrotic cells 18 hours
after the particular cell death commitment (Fig. 7D). Annexin-
V-positive apoptotic cells included comparable amounts of early
apoptotic (PI
2/Vn
2), late apoptotic (PI
+/Vn
2), and ‘very late’
apoptotic (PI
+/Vn
high) cells. In contrast, Annexin-V-positive
necrotic cells were mostly vitronectin highly positive and
contained less PI
+/Vn
2 and only very few PI
2/Vn
2 cells.
These results suggest that the progression of cell death resulting
in complete membrane permeabilization is much faster in
necrosis than in apoptosis.
Figure 3. Heparin inhibits the direct interaction between vitronectin and late apoptotic cells. Apoptosis was induced in Jurkat cells by
TRAIL in serum-free medium (containing 1% BSA) and left for 48 or 72 hours. (A) The late apoptotic cells were incubated in 30% human serum or
serum-free medium for 1 hour. The cells were stained with anti-vitronectin or isotype matched control antibodies followed by GAM-Alexa Fluor 488
antibody staining and analyzed by flow cytometry. Unstained cells and cells stained only with GAM-Alexa Fluor 488 served as additional controls.
Mean 6 SD, n=3. (B) The late apoptotic cells were incubated in 50% human serum or serum-free medium for 1 hour and stained with anti-
vitronectin or anti-albumin and GAM-Alexa Fluor 647 antibodies for flow cytometry analysis. Mean 6 SD, n=3. (C) The late apoptotic cells were
incubated in serum-free medium supplemented with various concentrations of human purified vitronectin for 1 hour. The cells were stained with
anti-vitronectin and GAM-Alexa Fluor 488 antibodies and analyzed by flow cytometry. Mean 6 SD, n=3. (D) The late apoptotic cells were incubated
in the presence of 30% human serum and various concentrations of EDTA, RGD, or heparin. The cells were stained with anti-vitronectin GAM-Alexa
Fluor 488 antibodies and analyzed by flow cytometry. Cells that were not pre-incubated in human serum served as negative controls. Mean 6 SD,
n=3. (E) Biotinylated human vitronectin was bound onto RBCs using biotin-streptavidin-biotin sandwich approach. RBCs were incubated in the
presence or absence of heparin (50 IU/ml) in serum-free RPMI at 37uC for 1 hour and subsequently stained with anti-vitronectin antibody for flow
cytometry analysis. RBCs without bound vitronectin were used as a negative control. One representative experiment of 2 is shown.
doi:10.1371/journal.pone.0019243.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19243Figure 4. Vitronectin binds inside damaged cells. (A) Viable and heat-induced necrotic cells were incubated in the presence (black line) or
absence (grey filled histogram) of human serum for 1 hour and stained with anti-vitronectin and GAM-Alexa Fluor 488 antibodies for flow cytometry
analysis. One representative experiment of 3 is shown. (B) Apoptosis was induced in Jurkat cells by TRAIL in serum-free medium. After 72 hours, cells
were incubated in 50% human serum for 1 hour. The cells were stained with anti-vitronectin and GAM-Alexa Fluor 647 antibodies followed by
Vitronectin in Late Apoptotic and Necrotic Cells
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19243Discussion
2E12 monoclonal antibody was reported to stain a subset of late
apoptotic cells cultured in vitro [5–6]. We identified the antigen
recognized by 2E12 antibody as a bovine serum protein
vitronectin that binds to apoptotic cells of various origin. Using
a human T-cell line Jurkat and human vitronectin, we found that
purified vitronectin binds late apoptotic cells in a dose-dependent
manner. This binding could be inhibited by heparin. Confocal
microscopy revealed that vitronectin binds inside the cells with
severely damaged membrane. Moreover, vitronectin was detected
in dead cells in mouse spleen and thymus suggesting that
vitronectin binds necrotic cells and cells at the terminal stage of
apoptosis in vivo.
Flow cytometry has been widely used to assess viability,
apoptosis, and/or necrosis on a single cell basis [32]. A common
method for detection of apoptotic cells is based on staining with
Annexin-V and a DNA-binding dye that does not penetrate intact
cell membrane (e.g. PI). Annexin-V-positive and PI-negative cells
are considered as ‘‘early apoptotic’’ while the double positive cells
are classified as ‘‘late apoptotic’’ or ‘‘necrotic’’. However, it has
been documented that the loss of the membrane integrity is a
gradual process. First, the membrane of a late apoptotic cell
becomes permeable for small molecules (PI) and subsequently
opens also for macromolecules [4,33–35]. The latter phase of
membrane damage is usually monitored as a leakage of lactate
dehydrogenase or other intracellular proteins using enzymatic
assays or immunoblotting. Our observations suggest that a simple
flow cytometry approach based on vitronectin staining can be used
to distinguish between the two subsets of late apoptotic cells on a
single cell level. Such classification of the apoptotic stages could be
biologically important. In contrast to vitronectin-positive cells, the
PI
+/Vn
2 cells can still retain macromolecules that could induce
immunogenic or inflammatory response in case of their escape [4].
We used this method to reveal that necrosis induced by oxidative
stress (hydrogen peroxide) or heating leads to complete membrane
permeabilization much faster than apoptosis. Apoptotic cells are
apparently able to keep their membranes non-permeable for
proteins and other macromolecules for some time even after they
become permeable for small charged molecules like propidium
iodide. Thus, they can extend the time needed for their clearance
before the potential auto-antigens are released into the body. In
contrast, necrotic cells become permeable for proteins either
immediately or shortly after the onset of necrosis.
Vitronectin is an abundant plasma glycoprotein and is a part of
the extracellular matrix [7,8,14,15]. While the plasma vitronectin
is produced mainly by the liver, the origin of the tissue vitronectin
is less clear [8]. Most probably the tissue vitronectin originates
mainly from the plasma vitronectin that is translocated across
endothelium via active transcytosis [8,36,37]. Alternatively,
vitronectin could be produced locally in the tissue. This is
supported by the detection of vitronectin mRNA in several tissues
albeit at much lower level than in the liver [8]. Vitronectin is
substantially enriched in the sites of inflamed, injured, necrotic,
and cancer tissues including cirrhotic liver, atherosclerotic plaques,
injured skin, Alzheimer plaques, myocardial infarction, and
Figure 5. Vitronectin-binding cytoplasmic components are not intermediate filaments. (A) HeLa cells were harvested by trypsinization,
fixed, and permeabilized. The cells were incubated in 50% human serum with (dashed line) or without heparin (50 IU/ml) (solid line) at 37uC for
1 hour. Afterwards, the cells were stained with anti-vitronectin and GAM-Alexa Fluor 647 antibodies and analyzed by flow cytometry. Cells not
incubated in human serum served as negative controls (grey filled histogram). (B) HeLa cells cultivated on microscope cover slips were fixed and
permeabilized. The cells were incubated in 50% human serum, stained with anti-vitronectin and GAM-Alexa Fluor 647 antibodies, followed by anti-
pan-cytokeratin-Alexa Fluor 488 and anti-vimentin-Dy 547 antibodies in 20% mouse serum and Hoechst 34580 staining.
doi:10.1371/journal.pone.0019243.g005
Annexin-V-FITC and Hoechst 34580. The cells were analyzed by confocal microscopy. Two representative cells (including a DNA-free apoptotic body)
are shown. AF647, Alexa Fluor 647.
doi:10.1371/journal.pone.0019243.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19243Figure 6. Vitronectin binds to dead cells in vivo. Single cell suspensions prepared from murine spleen (A) or thymus (B) were stained with
antibody to mouse vitronectin or isotype matched control antibody, followed by secondary goat anti-rat-APC antibody, or left unstained.
Simultaneously, staining with Hoechst 34580, PI, and Annexin-V-FITC was performed prior to flow cytometry analysis. Hoechst 34580 negative cells,
that were essentially Annexin-V-FITC and PI negative, were considered as viable cells (upper panels). Hoechst 34580/Annexin-V-FITC/PI-triple positive
cells were identified as dead cells (late apoptotic or necrotic) (upper right panels). APC-specific signal coming from staining with anti-vitronectin and
isotype matched control antibodies on the viable and dead cells is shown (lower panels). One representative experiment of 3 is shown.
doi:10.1371/journal.pone.0019243.g006
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atherosclerosis and Alzheimer disease are also associated with
defects in apoptotic cell clearance [3].
Little is known about the mechanisms regulating the delivery of
vitronectin specifically into the sites of injured tissue. Two possible
explanations were suggested: (1) vitronectin leakage from capil-
laries at the sites of injury and (2) an interaction between
vitronectin and a component specifically present in the stressed
tissue [8]. Here we show that vitronectin binds to necrotic and late
apoptotic cells in cell culture and in vivo. This supports the model
that vitronectin incorporation into the sites of injured, stressed,
and, possibly, also cancer tissue is at least partially dependent on
the interactions with a cytoplasmic component exposed after tissue
injury.
Vitronectin was shown to bind to in vitro prepared keratin
bodies and to keratinocyte derived Civatte bodies in patients
suffering from lichen ruber planus [30,42]. Moreover, vitronectin
was shown to interact with purified vimentin and with vimentin
exposed on the surface of activated platelets [31,43]. However, we
show here that the intracellular vitronectin-interacting structure is
diffusely distributed in the cytoplasm of viable cells and does not
co-localize with vimentin or cytokeratine filaments. Thus, the
binding of vitronectin to necrotic and late apoptotic cells is
apparently mediated mainly by a so far unidentified component
different from the intermediate cytoskeletal proteins.
Among numerous vitronectin binding receptors, aVb3, aVb5
integrins and the urokinase receptor are involved in the
recognition and engulfment of apoptotic cells by phagocytes
[2,44,45]. However, other ligands of these receptors, including
milk fat globule-EGF factor 8 and thrombospondin, were found to
mediate phagocytosis of apoptotic cells [3,46,47] while there was
only indirect evidence for possible vitronectin involvement [48–
50]. Despite numerous attempts, we did not observe any effects of
vitronectin opsonization on phagocytosis of the late apoptotic cells
Figure 7. Vitronectin can be used for monitoring of cell death progression. (A) Apoptosis was induced in the Jurkat cells with TRAIL for
24 hours in FBS-containing medium. The cells were harvested and incubated with biotinylated vitronectin on ice for 30 minutes followed by staining
with streptavidin-Alexa Fluor 488 and analyzed by flow cytometry. Non-treated cells and cells stained only with streptavidin were used as controls. (B)
Apoptosis was induced in the Jurkat cells with TRAIL in FBS-containing medium. At the indicated time points, the cells were harvested and incubated
with biotinylated vitronectin on ice for 30 minutes followed by staining with streptavidin-Alexa Fluor 488, propidium iodide, and Annexin-V-Dy647
and analyzed by flow cytometry. Non-treated cells and cells treated with TRAIL in combination with apoptosis inhibitor Z-VAD-FMK served as
controls. Mean 6 SD, n=3. (C) Jurkat cells were subjected to apoptosis (TRAIL) or necrosis (hydrogen peroxide in combination with Z-VAD-FMK)
induction in serum-free medium. At the indicated time points, the cells were harvested and incubated with biotinylated vitronectin on ice for
30 minutes followed by staining with streptavidin-Alexa Fluor 488 and flow cytometry analysis. Mean 6 SD, n=3. (D) Apoptosis (TRAIL) or necrosis
(hydrogen peroxide in combination with Z-VAD-FMK) was induced in Jurkat cells in serum-free medium. After 18 hours, the cells were harvested and
incubated with biotinylated vitronectin on ice for 30 minutes followed by staining with streptavidin-Alexa Fluor 488, propidium iodide, and Annexin-
V-Dy647 and analyzed by flow cytometry. The Annexin-V-positive cells were gated (left panel) and propidium iodide vs. vitronectin staining was
analyzed. Annexin-V
+/PI
2/Vn
2, Annexin-V
+/PI
+/Vn
+, Annexin-V
+/PI
+/Vn
high cells were gated (right panel). One representative experiment of 2 is
shown.
doi:10.1371/journal.pone.0019243.g007
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Accordingly, depletion of vitronectin from bovine serum also did
not induce any changes in phagocytosis of the late apoptotic cells
(not shown).
In conclusion, our observations that vitronectin binding does
not serve as an opsonization step to facilitate phagocytosis
indicates that this interaction may be rather relevant for other
biological roles of vitronectin in regeneration processes in injured
tissues (i.e. tissue remodeling, cell survival, and inflammation) that
were documented in several previously published studies [16–
18,21,22].
Supporting Information
Figure S1 2E12 antibody stains a subset of hypodiploid
cells of various species. Cell lines from different species were
stained with Hoechst 34580 and 2E12 antibody for flow cytometry
analysis. Human cell lines: JCaM2.5, Ramos, HL-60; chicken cell
line: DT40; rabbit cell line: 240E1; mouse cell lines: SP2/0, P815.
(TIF)
Figure S2 Human vitronectin binds to cells in the late
phases of apoptosis. Apoptosis was induced in Jurkat cells by
campthotecin. The cells were incubated in RPMI/10% human
AB serum. At indicated time points, cells were stained with
Annexin-V-FITC, propidium, and antibody to human vitronec-
tin+GAM-Alexa Fluor 647 and analyzed by flow cytometry. Mean
6 SD, n=3.
(TIF)
Figure S3 Vitronectin positive late apoptotic cells
exhibit low DNA content. Late apoptotic Jurkat cells were
incubated in human serum and stained with antibody to human
vitronectin followed by Alexa Fluor 647 conjugated secondary
antibody (red colour) and with DNA dye Hoechst 34580 (blue
colour). The white arrows point to vitronectin
low/DNA
high cells,
green arrows point to vitronectin
high/DNA
low cells.
(TIF)
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